Robin Annette Hylton

Array ( [id] => 16665100 [patent_doc_number] => 10934333 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-02 [patent_title] => Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers [patent_app_type] => utility [patent_app_number] => 16/915745 [patent_app_country] => US [patent_app_date] => 2020-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 41 [patent_no_of_words] => 98162 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16915745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16336536 [patent_doc_number] => 10787480 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-29 [patent_title] => Cytotoxic peptides and conjugates thereof [patent_app_type] => utility [patent_app_number] => 16/439204 [patent_app_country] => US [patent_app_date] => 2019-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 41 [patent_no_of_words] => 62597 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 682 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16439204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14774755 [patent_doc_number] => 20190262275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => MULTI-DIMENSIONAL STRUCTURES FROM PEPTOID OLIGOMERS AND METHODS OF MAKING [patent_app_type] => utility [patent_app_number] => 16/406869 [patent_app_country] => US [patent_app_date] => 2019-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16406869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715547 [patent_doc_number] => 20190248837 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer [patent_app_type] => utility [patent_app_number] => 16/393651 [patent_app_country] => US [patent_app_date] => 2019-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15667 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16393651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15114563 [patent_doc_number] => 20190343914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => PEPTIDOMIMETIC MACROCYCLES [patent_app_type] => utility [patent_app_number] => 16/223473 [patent_app_country] => US [patent_app_date] => 2018-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16223473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14158713 [patent_doc_number] => 20190106459 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/216773 [patent_app_country] => US [patent_app_date] => 2018-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17739 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16216773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15193869 [patent_doc_number] => 10494413 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-03 [patent_title] => Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers [patent_app_type] => utility [patent_app_number] => 16/212178 [patent_app_country] => US [patent_app_date] => 2018-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 41 [patent_no_of_words] => 98392 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16212178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14273721 [patent_doc_number] => 20190134145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => METHOD FOR TREATING COGNITIVE DYSFUNCTION [patent_app_type] => utility [patent_app_number] => 16/189833 [patent_app_country] => US [patent_app_date] => 2018-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5902 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16189833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16288899 [patent_doc_number] => 10765722 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-08 [patent_title] => Angiotensin II alone or in combination for the treatment of hypotension [patent_app_type] => utility [patent_app_number] => 16/135608 [patent_app_country] => US [patent_app_date] => 2018-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 10320 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16135608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14185231 [patent_doc_number] => 20190112320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES [patent_app_type] => utility [patent_app_number] => 16/129008 [patent_app_country] => US [patent_app_date] => 2018-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30611 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16129008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13729711 [patent_doc_number] => 20180369323 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => MODULATION OF HEPATITIS B VIRUS CCCDNA TRANSCRIPTION [patent_app_type] => utility [patent_app_number] => 16/115298 [patent_app_country] => US [patent_app_date] => 2018-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15827 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16115298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622063 [patent_doc_number] => 20180362583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => INTEGRIN INTERACTION INHIBITORS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/113869 [patent_app_country] => US [patent_app_date] => 2018-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16113869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622075 [patent_doc_number] => 20180362589 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/111027 [patent_app_country] => US [patent_app_date] => 2018-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 81946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16111027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13536601 [patent_doc_number] => 20180319844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => CYCLIC PEPTIDE BINDER AGAINST ONCOGENIC K-RAS [patent_app_type] => utility [patent_app_number] => 16/031840 [patent_app_country] => US [patent_app_date] => 2018-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16031840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13413191 [patent_doc_number] => 20180258138 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => Biologically Cleavable Tetrapeptide Linking Agents [patent_app_type] => utility [patent_app_number] => 15/990415 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14430 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15990415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13576921 [patent_doc_number] => 20180340009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-29 [patent_title] => PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 [patent_app_type] => utility [patent_app_number] => 15/982700 [patent_app_country] => US [patent_app_date] => 2018-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15982700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16184454 [patent_doc_number] => 10717758 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-21 [patent_title] => D-amino acid compounds for liver disease [patent_app_type] => utility [patent_app_number] => 15/981813 [patent_app_country] => US [patent_app_date] => 2018-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42169 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15981813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386401 [patent_doc_number] => 20180244742 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => Double-Acylated GLP-1 Derivatives [patent_app_type] => utility [patent_app_number] => 15/966642 [patent_app_country] => US [patent_app_date] => 2018-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15966642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386351 [patent_doc_number] => 20180244717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF [patent_app_type] => utility [patent_app_number] => 15/961531 [patent_app_country] => US [patent_app_date] => 2018-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62302 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 527 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15961531 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13368995 [patent_doc_number] => 20180236038 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => Liraglutide in cardiovascular conditions [patent_app_type] => utility [patent_app_number] => 15/956445 [patent_app_country] => US [patent_app_date] => 2018-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15956445 [rel_patent_id] =>[rel_patent_doc_number] =>)